 |
 Video: What is a Stock Split?
|
|
|
| Bio-Path Holdings is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company utilizing a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Co.'s primary drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2, initially started the efficacy portion of a Phase 2 clinical trial for untreated acute myeloid leukemia patients. Co.'s second drug candidate, Liposomal Bcl-2, targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Co.'s third drug candidate, Liposomal STAT3, targets the STAT3 protein. According to our BPTH split history records, Bio-Path Holdings has had 3 splits. | |
|
Bio-Path Holdings (BPTH) has 3 splits in our BPTH split history database. The first split for BPTH took place on February 09, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of BPTH owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. BPTH's second split took place on January 18, 2019. This was a 1 for 20 reverse split, meaning for each 20 shares of BPTH owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 5 share position following the split. BPTH's third split took place on February 23, 2024. This was a 1 for 20 reverse split, meaning for each 20 shares of BPTH owned pre-split, the shareholder now owned 1 share. For example, a 5 share position pre-split, became a 0.25 share position following the split.
When a company such as Bio-Path Holdings conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the BPTH split history from start to finish, an original position size of 1000 shares would have turned into 0.25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Bio-Path Holdings shares, starting with a $10,000 purchase of BPTH, presented on a split-history-adjusted basis factoring in the complete BPTH split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/10/2014 |
|
| End date: |
10/08/2024 |
|
| Start price/share: |
$8,400.00 |
|
| End price/share: |
$1.19 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.99% |
|
| Average Annual Total Return: |
-58.77% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1.42 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 02/09/2018 | 1 for 10 | | 01/18/2019 | 1 for 20 | | 02/23/2024 | 1 for 20 |
|
|
Free BPTH Email Alerts:
